Bay Area start­up Cor­texyme gains a $76M round to back a PhII Alzheimer's study, with a new tar­get in their sights

With the ev­i­dence in­creas­ing­ly weigh­ing in against amy­loid be­ta as the best so­lo tar­get for Alzheimer’s, a start­up out of San Fran­cis­co has iden­ti­fied a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA